Company / FCF Margin
Jazz Pharmaceuticals FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
30.4%
FY2025
5-year range
27.9% / 37.4%
FY2021-FY2025
Trend
-8.9%
vs FY2024
Sector context
#15 of 133
Health Care
What the data says
Jazz Pharmaceuticals's fcf margin of 30.4% is higher than 89% of companies in the Health Care sector (FY2025). FCF Margin has fluctuated over the past 10 years, ranging from 27.9% in FY2023 to 176.6% in FY2017.
Based on SEC 10-K filings.
30.4% in FY2025 with a 5-year CAGR of -10.8%. Top quartile in the Health Care sector.
Improved from 27.9% to 30.4% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -7.0pp
- 5-Year Change
- -10.8pp
- 10-Year Change
- -
Sector benchmark
Top 11% in Health CareTop 11% of 133This company 30.4% Sector average -632.8%
▼
+104.8% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 8.9% year-over-year.
- Currently 663.2pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2017.
- Lowest fcf margin in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 30.4% | -8.9% |
| FY2024 | 33.4% | +19.8% |
| FY2023 | 27.9% | -25.6% |
| FY2022 | 37.4% | +9.9% |
| FY2021 | 34.1% | -17.3% |
| FY2020 | 41.2% | +0.3% |
| FY2019 | 41.0% | +4.8% |
| FY2018 | 39.2% | -77.8% |
| FY2017 | 176.6% | +458.0% |
| FY2016 | 31.6% | -15.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026